Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM

Summary

Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM is a clinical trial^[1].

Key Facts

• Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM is in the country of Canada^[2].
• Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM is in the country of United States^[3].
• Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM's instance of is recorded as clinical trial^[4].
• Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM's start time is recorded as +2014-04-30T00:00:00Z^[5].
• Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM's end time is recorded as +2019-05-31T00:00:00Z^[6].
• Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM's main subject is recorded as hypertrophy^[7].
• Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM's number of participants is recorded as {'unit': '1', 'amount': '+211'}^[8].
• Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM's title is recorded as Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM^[9].
• Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM's short name is recorded as VANISH^[10].
• Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+8'}^[11].
• Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM's ClinicalTrials.gov ID is recorded as NCT01912534^[12].
• Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+45'}^[13].
• Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM's research intervention is recorded as Valsartan/hydrochlorothiazide^[14].
• Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM's clinical trial phase is recorded as phase II clinical trial^[15].
• Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM's research site is recorded as Stanford University^[16].
• Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM's research site is recorded as University of Chicago^[17].
• Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM's research site is recorded as Harvard University^[18].
• Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM's research site is recorded as Cincinnati Children's Hospital Medical Center^[19].
• Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM's research site is recorded as Cleveland Clinic^[20].
• Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM's research site is recorded as University of Pennsylvania^[21].
• Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM's research site is recorded as University of Toronto^[22].
• Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM's research site is recorded as University of Colorado Denver^[23].
• Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM's research site is recorded as Johns Hopkins University^[24].
• Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM's research site is recorded as University of Michigan^[25].
• Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM's research site is recorded as Children's Hospital of Philadelphia^[26].